Abstract:Activation of the Nod-like receptor 3 (NLRP3) inflammasome is important for activation of innate immune responses, but improper and excessive activation can cause inflammatory disease. We previously showed that glycolysis, a metabolic pathway that converts glucose into pyruvate, is essential for NLRP3 inflammasome activation in macrophages. Here, we investigated the role of metabolic pathways downstream glycolysis – lactic acid fermentation and pyruvate oxidation—in activation of the NLRP3 inflammasome. Using pharmacological or genetic approaches, we show that decreasing lactic acid fermentation by inhibiting lactate dehydrogenase reduced caspase-1 activation and IL-1β maturation in response to various NLRP3 inflammasome agonists such as nigericin, ATP, monosodium urate (MSU) crystals, or alum, indicating that lactic acid fermentation is required for NLRP3 inflammasome activation. Inhibition of lactate dehydrogenase with GSK2837808A reduced lactate production and activity of the NLRP3 inflammasome regulator, phosphorylated protein kinase R (PKR), but did not reduce the common trigger of NLRP3 inflammasome, potassium efflux, or reactive oxygen species (ROS) production. By contrast, decreasing the activity of pyruvate oxidation by depletion of either mitochondrial pyruvate carrier 2 (MPC2) or pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1) enhanced NLRP3 inflammasome activation, suggesting that inhibition of mitochondrial pyruvate transport enhanced lactic acid fermentation. Moreover, treatment with GSK2837808A reduced MSU-mediated peritonitis in mice, a disease model used for studying the consequences of NLRP3 inflammasome activation. Our results suggest that lactic acid fermentation is important for NLRP3 inflammasome activation, while pyruvate oxidation is not. Thus, reprograming pyruvate metabolism in mitochondria and in the cytoplasm should be considered as a novel strategy for the treatment of NLRP3 inflammasome-associated diseases.

Fatty acid synthesis promotes inflammasome activation through NLRP3 palmitoylation

Phosphodiesterase 4B is Required for NLRP3 Inflammasome Activation by Positive Feedback with Nrf2 in the Early Phase of LPS- Induced Acute Lung Injury

Consecutive palmitoylation and phosphorylation orchestrates NLRP3 membrane trafficking and inflammasome activation

From fat to fire: The lipid–inflammasome connection

Palmitoylation prevents sustained inflammation by limiting NLRP3 inflammasome activation through chaperone-mediated autophagy

Initiation and perpetuation of NLRP3 inflammasome activation and assembly

NLRP3 inflammasome mediate palmitate-induced endothelial dysfunction

NLRP3 Cys126 palmitoylation by ZDHHC7 promotes inflammasome activation

Palmitoylation promotes chaperone-mediated autophagic degradation of NLRP3 to modulate inflammation

How location and cellular signaling combine to activate the NLRP3 inflammasome

NLRP3 inflammasome activation, metabolic danger signals, and protein binding partners

Regulation of NLRP3 Inflammasome by Phosphorylation

Regulation of the NLRP3 inflammasome by autophagy and mitophagy

Toll-like receptor mediated inflammation requires FASN-dependent MYD88 palmitoylation

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH

NLRP3 inflammasome assembly is regulated by phosphorylation of the pyrin domain

Metabolic Regulation of the NLRP3 Inflammasome

Acetylation is required for full activation of the NLRP3 inflammasome

The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation

NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation

Lactic Acid Fermentation Is Required for NLRP3 Inflammasome Activation